SHL TelemedicineSHMLF 52 Return-on-Tangible-Equity is -352.05% as of Dec. 2025. GuruFocus rates SHMLF with a GF Score™ of 52/100 and a GF Value™ of $12.09. The stock has 3 warning signs investors should review. Among 580 Healthcare Providers & Services companies, SHL Telemedicine ranks worse than 96.72% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. SHL Telemedicine's annualized net income for the quarter that ended in Dec. 2025 was $-22.06 Mil. SHL Telemedicine's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $6.27 Mil. Therefore, SHL Telemedicine's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -352.05%.
The historical rank and industry rank for SHL Telemedicine's Return-on-Tangible-Equity or its related term are showing as below:
SHMLF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1825.83 Med: -116.69 Max: 490.61
Current: -265.11
During the past 13 years, SHL Telemedicine's highest Return-on-Tangible-Equity was 490.61%. The lowest was -1,825.83%. And the median was -116.69%.
SHMLF's Return-on-Tangible-Equity is ranked worse than 96.72% of 580
companies
in the Healthcare Providers & Services industry
Industry Median: 10.065
vs SHMLF: -265.11
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
SHL Telemedicine Return-on-Tangible-Equity Related Terms
SHL Telemedicine Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for SHL Telemedicine's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHMLF vs VEEV, BTSG, TEM: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, SHL Telemedicine's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SHL Telemedicine Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where SHL Telemedicine's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -352.05% mean?
SHL Telemedicine (SHMLF) has a Return-on-Tangible-Equity of -352.05% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SHL Telemedicine and its competitors. According to the industry distribution chart, SHL Telemedicine ranks #561 out of 580 companies in the Healthcare Providers & Services industry, placing it in the top 96.7%.
Is SHL Telemedicine's Return-on-Tangible-Equity too high?
SHL Telemedicine's current Return-on-Tangible-Equity is -352.05%. Based on the distribution chart, SHL Telemedicine ranks #561 out of 580 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, SHL Telemedicine has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's Return-on-Tangible-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SHL Telemedicine ranks #561 out of 580 companies for Return-on-Tangible-Equity. This places SHL Telemedicine in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.07, based on 580 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SHL Telemedicine and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SHL Telemedicine's current Return-on-Tangible-Equity is -352.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
SHL Telemedicine (SHMLF) has a current Return-on-Tangible-Equity of -352.05%. The stock's GF Value™ is $12.09, compared to a current price of $4.84 — trading 59.9% below its estimated fair value. The current Return-on-Tangible-Equity is -352.05%. SHL Telemedicine's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For SHL Telemedicine (SHMLF), the current Return-on-Tangible-Equity is -352.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SHL Telemedicine (SHMLF) Overvalued in 2026?
Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued.
The current stock price of $4.84 is trading 59.9% below its estimated GF Value™ of $12.09.
Key valuation signals for SHMLF:
Return-on-Tangible-Equity: -352.05%
GF Value™: $12.09 vs. price of $4.84 (59.9% below fair value)
No single metric tells the full story. See the SHMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
52GF Score
Get the complete analysis for SHMLF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHMLF has been successfully added to your 
